Pharmacovigilance (PV) is the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problem.
In simpler terms, it is the ongoing process of:
-
Monitoring the safety of medicines (and other health products) throughout their entire life cycle, from clinical trials to widespread public use.
-
Identifying new or changing risks (side effects).
-
Evaluating these risks to understand their severity and frequency.
-
Taking action to minimize risks and maximize benefits, such as updating warning labels, restricting use, or, in rare cases, removing a product from the market.
-
Informing healthcare professionals and the public to ensure medicines are used as safely as possible.
The ultimate goal of pharmacovigilance is patient safety and public health.
History of Pharmacovigilance
While doctors have always observed drug effects, modern pharmacovigilance began as a formal science in the 20th century, driven by tragic events.
-
Pre-20th Century: Informal observation of drug effects.
-
1937 – The Elixir Sulfanilamide Tragedy (USA): A toxic solvent in a liquid medication caused over 100 deaths, mostly children. This led to the U.S. Federal Food, Drug, and Cosmetic Act of 1938, which required drugs to be proven safe before marketing.
-
1961 – The Thalidomide Disaster: This was the pivotal moment. Thalidomide, prescribed for morning sickness, caused severe birth defects (phocomelia) in thousands of babies worldwide. It revealed that drugs could cause rare but devastating effects not detected in pre-market testing.
-
1968 – The WHO Programme for International Drug Monitoring (PIDM): In response to the thalidomide tragedy, the World Health Organization (WHO) established this program to collect and analyze adverse drug reaction (ADR) reports from around the world. The Uppsala Monitoring Centre (UMC) in Sweden was established in 1978 as the WHO collaborating centre for this program.
-
1990s – 2000s – Harmonization and Strengthening: Regulations were strengthened globally. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) was formed to create unified safety standards across Europe, Japan, and the USA. The European Medicines Agency (EMA) was established in 1995.
-
21st Century – Proactive and Data-Driven: The field has evolved from passive reporting to proactive risk management, using advanced data analytics, social media listening, and real-world evidence from electronic health records.
Key Institutions in Pharmacovigilance (International and Local)
A. International and Regional Institutions
-
World Health Organization (WHO) – Uppsala Monitoring Centre (UMC):
-
Role: The global leader. It manages VigiBase, the world’s largest database of individual case safety reports (ICSRs), with data from over 170 member countries. It identifies potential safety signals from this global data.
-
-
International Council for Harmonisation (ICH):
-
Role: Develops international technical guidelines (like ICH E2A-E2F) for pharmacovigilance to ensure consistency in how drug safety is monitored and reported across different regions.
-
-
European Medicines Agency (EMA) – Pharmacovigilance Risk Assessment Committee (PRAC):
-
Role: The key regulatory body in the European Union (EU). The PRAC is responsible for assessing and monitoring the safety of human medicines across the EU and making recommendations.
-
-
U.S. Food and Drug Administration (FDA) – Center for Drug Evaluation and Research (CDER):
-
Role: The U.S. regulatory authority. It operates the FDA Adverse Event Reporting System (FAERS) and mandates risk evaluation and mitigation strategies (REMS) for high-risk drugs.
-
B. Local/National Institutions (Examples)
-
Egyptian Drug Authority (EDA) – Egyptian Pharmaceutical Vigilance Center (EPVC):
-
Role: The national regulatory body in Egypt responsible for pharmacovigilance. The EPVC (as seen in the newsletters) collects ADR reports from healthcare professionals and the public, conducts safety reviews, issues national safety alerts, and participates in international monitoring through the WHO programme.
-
-
United Kingdom – Medicines and Healthcare products Regulatory Agency (MHRA):
-
Role: The UK’s regulator, which runs the “Yellow Card Scheme” for ADR reporting.
-
-
Japan – Pharmaceuticals and Medical Devices Agency (PMDA):
-
Role: Japan’s regulatory agency, which conducts safety monitoring and assessment.
-
Branches of Pharmacovigilance
The field of pharmacovigilance has several specialized branches:
-
Operational Pharmacovigilance: The core activities. This includes:
-
Case Processing: Receiving, recording, and managing Individual Case Safety Reports (ICSRs).
-
Triaging: Determining the seriousness and expectedness of reported events.
-
Database Management: Entering data into safety databases like VigiFlow or Argus.
-
-
Surveillance and Signal Detection:
-
Signal Detection: Proactively searching for new safety concerns from various sources (databases, medical literature, etc.).
-
Signal Validation and Assessment: Investigating potential signals to determine if they represent a new risk.
-
-
Risk Management:
-
Risk Management Planning: Developing and implementing Risk Management Plans (RMPs) for new medicines to proactively identify, characterize, and minimize risks.
-
Risk Minimization: Implementing tools like additional educational materials for doctors or controlled distribution systems for high-risk drugs.
-
-
Systems and Processes Pharmacovigilance:
-
Focuses on developing and maintaining the quality systems, standard operating procedures (SOPs), and technology infrastructure that support all PV activities.
-
-
Quality and Compliance:
-
Ensures that all pharmacovigilance activities comply with global and local regulations. This includes preparing for and managing regulatory inspections.
-
-
Medical Writing (Pharmacovigilance):
-
Specializes in writing safety documents, such as Periodic Safety Update Reports (PSURs), Development Safety Update Reports (DSURs), and expert statements for regulatory submissions.
-
-
Pharmacoepidemiology:
-
Uses epidemiological methods to study drug effects in large populations. It analyzes real-world data to quantify risks and benefits.
-
